A Multicenter Phase II Open Label Study to Evaluate Efficacy of Concomitant Use of Pembrolizumab and Entinostat in Adult Patients With Metastatic Uveal Melanoma
Phase of Trial: Phase II
Latest Information Update: 26 Feb 2018
At a glance
- Drugs Entinostat (Primary) ; Pembrolizumab (Primary)
- Indications Uveal melanoma
- Focus Therapeutic Use
- Acronyms PEMDAC
- 22 Feb 2018 Planned End Date changed from 1 Jul 2023 to 1 Aug 2023.
- 22 Feb 2018 Planned primary completion date changed from 1 Jul 2021 to 1 Aug 2021.
- 29 Jan 2018 Status changed from not yet recruiting to recruiting.